Abiraterone and metastatic prostate cancer: delays pain onset, cytotoxic therapy, and possibly death.
When metastatic prostate cancer progresses despite androgen suppression but symptoms do not yet warrant cytotoxic therapy, abiraterone appears to prolong overall survival and to delay the onset of some cancer-related symptoms. But beware of cardiac and hepatic adverse effects that are inadequately documented.